By proceeding, you agree to our Terms of Use and Privacy Policy.
Lei Shi is a distinguished researcher and innovator with a prolific track record in the fields of cancer immunotherapy, cancer stem cells, and metastasis. During his Ph.D. training, Lei developed a groundbreaking delivery and expression system that harnessed both prokaryotic and eukaryotic elements to generate therapeutic factors through an autocatalytic feedback loop, a pioneering approach that found application in cancer immunotherapy. His work resulted in the grant of two US patents and the publication of 10 influential research papers. Lei's entrepreneurial spirit shone through as he co-founded Sal Vectors, a pharmaceutical company dedicated to advancing bacteria-based cancer immunotherapies for canines and humans, securing crucial investments along the way. His research at the University of Hong Kong unveiled critical insights into the roles of Sirtuins and HDACs in cancer stem cell metastasis and conducted groundbreaking genome-wide CRISPR/Cas9-mediated high-throughput screens to identify key drivers in multi-organ site metastases. His contributions have been published in prestigious journals such as Nature Communications and Oncogene. Since joining MD Anderson in 2018, Lei has continued to make significant strides, actively engaging in numerous projects that have culminated in nine published manuscripts, including as a first author in leading journals like Cancer Cell and PNAS. Lei Shi's dedication to advancing the field of oncology through cutting-edge research and translational efforts marks him as a true luminary in the scientific community.
Talks About #syntheticbiology
Preferred Locations #NorthAmerica